Apollo Hospitals Reports Strong Q4 FY26 Results and Strategic Divestments

Apollo Hospitals Enterprise Limited announced its financial results for the fourth quarter and full year of FY26, revealing a significant 36% year-on-year increase in consolidated profit after tax (PAT) to ₹529 crore for Q4 FY26. For the full year FY26, consolidated PAT grew 34% to ₹1,942 crore. The company also reported healthy revenue growth, with Q4 FY26 consolidated revenue rising 18% to ₹6,605 crore and full-year revenue up 16% to ₹25,229 crore.

Strategic Divestment and Consolidation

These strong financial results highlight the company's expanding operational scale and profitability. In a strategic move to focus on core areas and unlock value, Apollo Hospitals plans to divest stakes in Apollo Specialty Hospitals Pvt Ltd (ASHPL) and Apollo Fertility Centres Pvt Ltd (AFCPL) to Kids Clinic India Limited for an enterprise value of ₹1,550 crore. Additionally, the merger of Apollo Hospitals North Ltd into the parent company is set to consolidate operations and simplify the group's corporate structure.

Shareholder Returns and Corporate Structure Changes

The divestment of ASHPL and AFCPL means these entities will no longer be subsidiaries of Apollo Hospitals. The merger of Apollo Hospitals North Ltd will further streamline the group's corporate structure. The Board has also recommended a final dividend of ₹10 per equity share, pending shareholder approval at the upcoming Annual General Meeting.

Legal Challenge in Karnataka

Apollo Hospitals is currently navigating a legal challenge in Karnataka, where a subsidiary is contesting a land grant cancellation order. Although an interim stay has been secured from the High Court, the eventual resolution of this matter remains a key point to monitor.

Key Financial Metrics

• Q4 FY26 Consolidated Revenue: ₹6,605 crore (+18% YoY)
• Q4 FY26 Consolidated PAT: ₹529 crore (+36% YoY)
• FY26 Consolidated Revenue: ₹25,229 crore (+16% YoY)
• FY26 Consolidated PAT: ₹1,942 crore (+34% YoY)
• Divestment Transaction Value: ₹1,550 crore

What to Watch Next

Investors will be closely observing the necessary regulatory approvals for the divestment and merger processes. Shareholder approval at the Annual General Meeting on August 25, 2026, will be crucial for key appointments and the potential merger. Monitoring the progress of the legal matter concerning the land grant in Karnataka is also important for the company's operational outlook.